key: cord-0801880-vou9qbl5
authors: Arce Gálvez, Leonado; Ramírez Abadía, Laura Andrea; de los Reyes Guevara, Carlos Alfonso; Hernández Orozco, John Faber
title: Guillain-Barre syndrome after vaccination for Covid-19. The first report in Latin America
date: 2021-09-16
journal: Neurology Perspectives
DOI: 10.1016/j.neurop.2021.09.002
sha: 62acd730cdd9a9039c6ae813a16d15b6de164876
doc_id: 801880
cord_uid: vou9qbl5

nan

Vaccines can have rare, varied adverse effects including neurological entities. Guillain-Barre syndrome (GBS) is associated with multiple infectious agents including COVID-19 [4] , it has also been reported after vaccination of polio, hepatitis B, rabies, and influenza in periods from 2 days to 3 weeks [5] ; recently one case of GBS has been reported with the Pfizer vaccine for COVID-19 [6] and two cases in the Johnson & Johnson vaccine studies [7] . Although this does not generate a causal relationship, it creates the need to follow up all patients vaccinated for COVID-19 who develop neurological pathologies, to increase the evidence and favor a precise medical approach with timely treatments in complex neurological conditions. We report the case of a 73-year-old man, from Cali-Colombia, who consults a national reference university hospital in march 2021, with four-day symptoms consisting of upper limb (UL) paresis, posterior lower limb involvement (LL) associated with an inability to walk, and dyspnea. Four days before the onset of symptoms, the patient had received the first dose of vaccination for COVID-19-Sinovac. Upon admission to the emergency department, he presented flaccid symmetric quadriparesis with muscle strength in UL of 1/5 and bilateral LL 2/5, generalized hyporeflexia, without sensory alteration or sphincter involvement, without upper motor neuron signs; they suspected motor poly-neuroradiculopathy with a descending pattern and a high risk of ventilatory failure, for which he was admitted to the intensive care unit with oxygen support, 24 hours later with deterioration of the respiratory pattern and a requirement for orotracheal intubation. The patient had a history of GBS 20 years ago, without information on medical history or management, does not report other relevant personal or family history, nor febrile, gastrointestinal, or respiratory episodes in the last month.

Lumbar puncture was performed with opening pressure of 21 cm/H2O, cytochemical Acknowledgments: To the Hospital Universitario del Valle Evaristo García E.S.E and its department of electro-diagnosis and clinical neurology. GBS-REHABILITATION GOALS.

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac -PROFISCOV: A structured summary of a

Síndrome de Guillain-Barré asociado a COVID-19: diagnóstico, tratamiento y rehabilitación

Vaccines and the risk of Guillain-Barré syndrome

Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine